when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

mRNA Therapeutic · news · pharmadog

← back to mRNA Therapeutic

News · mRNA Therapeutic

173 stories

27dNovartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappointsbiospace

27d4 CDMOs to consider when outsourcing manufacturingbiospace

27dModerna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’biospace

29dAbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapiesfiercebiotech

Sep 4, 26Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipelinefiercebiotech

Sep 3, 26US to grant up to $125M for personalized RNA manufacturing innovationbiospace

Sep 2, 26UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapybiopharma dive

Sep 2, 26Teva claims success in celiac study; BioMarin, Ascendis settle patent disputebiopharma dive

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Sep 1, 26Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?fiercebiotech

Sep 1, 26GSK to launch Phase 3 test of mRNA flu vaccine with newer formulationendpoints

Sep 1, 26GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modalitybiospace

Sep 1, 26STAT+: Novartis gets multiple sclerosis win with BTK inhibitorstat

Sep 1, 26STAT+: Will House delay Trump plan to politicize NIH grants?stat

Sep 1, 26GSK catches phase 3 fever after mRNA flu vaccine beats standard shotsfiercebiotech

Aug 31, 26STAT+: Trump strikes nine more deals with drugmakers to lower pricesstat

Aug 31, 26ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CMfiercebiotech

Aug 31, 26STAT+: Can a pregnancy hormone steer a cardiovascular treatment?stat

Aug 31, 26A winner, a loser, and a mid-stage signal from a major cardiology research conferencestat

Aug 31, 26STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapystat

Aug 31, 26STAT+: After a rough stretch, mRNA gets a boost — at least for nowstat

Aug 28, 26BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancerbiospace

Aug 28, 26Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccinesbiopharma dive

Aug 28, 26BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccineendpoints

Aug 28, 26BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 testfiercebiotech

Aug 28, 26AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyondfiercebiotech

Aug 28, 26Genentech doubles down on ADC-resistant cancers with $1B DualityBio pactfiercebiotech

Aug 27, 26Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 winsendpoints

Aug 27, 26What’s in Merck and Moderna’s cancer vaccine algorithm?stat

Aug 27, 26STAT+: Cassidy criticizes FDA oversight of abortion pill manufacturers in new reportstat

← prevpage 2 of 6next →